New Product Technology


New Spinal Cord Stimulator System Targets Chronic Pain Relief

Boston Scientific Corporation’s new spinal cord stimulator (SCS) system has received CE Mark approval and is currently being launched into the European Market, according to a news release from the Natick, Mass-based company. The Precision Spectra SCS System is comprised of 32 contacts and 32 dedicated power sources.

The device is engineered to offer a wide range of chronic pain patients improved pain relief. The release notes that the first commercial implant of the Precision Spectra SCS System was performed last month at the Basildon and Thurrock University Hospitals in the UK.

The company reports that the spinal cord stimulators deliver electrical pulses from an implantable pulse generator to leads with stimulating contacts, masking pain signals traveling to the brain. The addition of 32 contacts to the device is intended to provide users with more coverage of the spinal cord in order to bolster chronic pain management. The additional lead ports also reportedly offer physicians more flexibility to treat patients at the time of implementation and allow for more flexibility to adapt to changing pain patterns.

SCS systems have evolved from four to eight to 16 contacts, according to Simon Thompson, MBBS FRCA FIPP FFPMRCA , who performed the commercial implantation of the device at Basildon and Thurrock University Hospitals. “Now, by doubling the number of contacts to 32 while providing a dedicated power source each contact, the Precision Spectra System advances our ability to provide pain relief,” Thompson says.

Maulik Nanavaty, president of the Neuromodulation business, Boston Scientific, echoes Thompson’ s sentiment, emphasizing the company’s focus on pain relief. Nanavaty adds the device reflects the company’s, “commitment to providing improved pain relief to a broader spectrum of chronic pain patients.”

The release notes that while the company has recently begun trials of the Precision Spectra SCS System, the US Food and Drug Administration (FDA) is currently reviewing the device and it is not yet available in the US.

Source: Boston Scientific Neuromodulation